HepaRegeniX publishes data for its first-in-class MKK4 ...
HepaRegeniX's HRX-215, a first-in-class MKK4 inhibitor, shows promise in treating liver diseases by enhancing liver regeneration and preventing liver failure, as evidenced by clinical and preclinical data. Safe and well-tolerated in healthy volunteers, it aims to revolutionize liver surgery and transplantation, with Phase II studies planned.
Reference News
HepaRegeniX's HRX-215, a first-in-class MKK4 inhibitor, shows promise in treating liver diseases by enhancing liver regeneration and preventing liver failure, as evidenced by clinical and preclinical data. Safe and well-tolerated in healthy volunteers, it aims to revolutionize liver surgery and transplantation, with Phase II studies planned.
HRX-215, a novel MKK4 inhibitor by HepaRegeniX, showed safety and enhanced liver regeneration in clinical and preclinical trials. It aims to revolutionize liver surgery and transplantation by preventing post-hepatectomy liver failure and addressing organ shortage. Published in Cell, it marks a significant advancement in treating liver diseases.